Dr. Richeng Jiang 蒋日成
Chief Physician, Associate Professor
Department of Medical Oncology I, Tianjin Medical University Cancer Institute & Hospital, Tianjin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, targeted therapy, and gene immunotherapy for lung cancer. Focuses on early diagnosis, comprehensive care, and personalized treatment strategies.
Dr. Jiang holds a PhD in oncology and completed postdoctoral research at Columbia University and the University of Maryland (2007–2009), supported by a US Department of Defense grant. Previously conducted research in France (2005). Since 2009, has served as Chief Physician and Associate Professor at Tianjin Medical University Cancer Institute & Hospital, focusing on lung cancer mechanisms and drug resistance.
Name order: in Chinese the family name comes first (Jiang Richeng). Papers usually list the name as Richeng Jiang or Jiang R.
Selected publications
41 papers on PubMed matched by name and affiliation; 24 as first or senior author since 2016. Most recent first- or senior-author papers:
- BMC Med, 2025 (senior author): Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis. PubMed 40234867
- J Thorac Dis, 2025 (senior author): PLCXD3-ALK, a novel ALK rearrangement in lung squamous cell carcinoma and its clinical responses to ALK inhibitors. PubMed 39975736
- Clin Lung Cancer, 2024 (senior author): Response to Editor: Commentary on "Influence of Tumor Cavitation on Assessing the Clinical Benefit of Anti-PD1 or PD-L1 Inhibitors in Advanced Lung Squamous Cell Carcinoma". PubMed 39317616
- Cell Death Dis, 2024 (senior author): PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer. PubMed 39227379
- Oncogene, 2024 (senior author): PIM1/NF-κB/CCL2 blockade enhances anti-PD-1 therapy response by modulating macrophage infiltration and polarization in tumor microenvironment of NSCLC. PubMed 39004633
- Clin Lung Cancer, 2024 (senior author): Influence of Tumor Cavitation on Assessing the Clinical Benefit of Anti-PD1 or PD-L1 Inhibitors in Advanced Lung Squamous Cell Carcinoma. PubMed 38008641
- Cancer Pathog Ther, 2023 (senior author): Pan-cancer analysis of the prognostic and immunological role of nucleophosmin/nucleoplasmin 3 (NPM3) and its potential significance in lung adenocarcinoma. PubMed 38327603
- J Cancer Res Clin Oncol, 2023 (senior author): Investigation and verification of GIMAP6 as a robust biomarker for prognosis and tumor immunity in lung adenocarcinoma. PubMed 37338641
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion